The teleost ®sh are widely used as model organisms in vertebrate biology. The compact genome of the puffer®sh, Fugu rubripes, has proven a valuable tool in comparative genome analyses, aiding the annotation of mammalian genomes and the identi®-cation of conserved regulatory elements, whilst the zebra®sh is particularly suited to genetic and developmental studies. We demonstrate that a puffer®sh WT1 transgene can be expressed and spliced appropriately in transgenic zebra®sh, contrasting with the situation in transgenic mice. By creating both transgenic mice and transgenic zebra®sh with the same construct, we show that Fugu RNA is processed correctly in zebra®sh but not in mice. Furthermore, we show for the ®rst time that a Fugu genomic construct can produce protein in transgenic zebra®sh: a full-length Fugu WT1 transgene with a C-terminal b-galactosidase fusion is spliced and translated correctly in zebra®sh, mimicking the expression of the endogenous WT1 gene. These data demonstrate that the zebra®sh:Fugu system is a powerful and convenient tool for dissecting both vertebrate gene regulation and gene function in vivo.
INTRODUCTION
The Wilms' tumour suppressor gene, WT1, was originally identi®ed as a gene deleted or rearranged in Wilms' tumour (1, 2) , and WT1 mutations have been shown to cause both Frasier (3) and Denys±Drash (4) syndromes. The gene encodes a four zinc ®nger-containing nuclear protein with roles both as a transcription factor and in RNA processing [reviewed in Englert (5) ]. In addition to human genitourinary disorders, further evidence of the fundamental role of WT1 in genitourinary development is provided by WT1-null mice, which display a complete absence of kidney and gonad structures and die in mid-gestation (6) . A combination of alternative splicing, alternative translation initiation and RNA editing gives rise to at least 16 distinct protein isoforms (5, 7, 8) .
WT1 has been conserved throughout vertebrate evolution, although only mammals possess numerous protein isoforms (9, 10) . Non-mammalian vertebrates possess just two different protein isoforms resulting from an alternative splicing event which can insert three amino acids between the third and fourth zinc ®ngers. Given that the genitourinary system has evolved dramatically throughout vertebrate radiation, it is tempting to speculate that the complexity of mammalian WT1 isoforms may be associated with changes to the genitourinary system, whilst the three amino acid alternative splice is involved in a basic function conserved through vertebrate evolution (11) . The expression pattern of WT1 has been conserved throughout vertebrates, with WT1 expression being demonstrated in the developing genitourinary system of chick, alligator, Xenopus and zebra®sh, as well as mammals (9,12±15 ). However, it should be noted that WT1 is also expressed in genitourinary structures that are speci®c to mammals, such as the endometrium (16) . Consequently, whilst evolutionary conservation may point to the basic function(s) of WT1, evolutionary differences could shed light on the acquisition of novel regulatory and functional properties during the evolution of an organ system.
The puffer®sh, Fugu rubripes, has a genome that is approximately 7.5 times smaller than that of human, with compaction occurring within both introns and intergenic regions (17) . The relatively small size of the Fugu genome has enabled a large amount of sequence data to be generated (18) (http://fugu.hgmp.mrc.ac.uk), thereby facilitating base-bybase comparison of ®sh and mammalian genomes (e.g. Fugu:human) and providing a framework onto which other genomes such as zebra®sh and mouse may be superimposed. Typically, coding sequences are highly conserved between Fugu and mammals, and the randomisation of non-coding DNA sequences has led to the identi®cation of regulatory elements associated with genes based upon non-coding DNA sequence conservation (19) . Recent studies have demonstrated the usefulness of zebra®sh transgenesis as a means of dissecting complex regulatory elements of Fugu genes (20) . The strategy of using Fugu transgenes in zebra®sh bene®ts from being a heterologous system, with the transgene readily *To whom correspondence should be addressed. distinguishable from the endogenous gene, without the drawbacks of using evolutionarily distant species such as mouse in which high level tissue-speci®c expression of transgenes is not guaranteed (21) . Despite the widespread use of Fugu as a model organism for genome comparisons and the proven worth of utilising its compact genome to identify and characterise regulatory elements, entire Fugu genes have not been exploited for functional studies. The compact nature of Fugu genes suggests they would be a very useful source of genomic DNA constructs for transgenesis, with the advantage over cDNA constructs of being able to generate all isoforms of a particular gene, expressed from their own regulatory elements. The recently sequenced human genome (22, 23) possesses fewer genes than predicted, and it has been suggested that alternative splicing may account for this discrepancy, resulting in a proteome of far greater complexity than the genome (24) . Consequently, the ability to express all isoforms of a particular gene for functional studies is an important consideration.
To evaluate the potential of Fugu transgenes, Sathasivam et al. introduced the Fugu homologue of the Huntingdon's disease gene into a mouse cell line and created a line of transgenic mice harbouring a genomic Fugu HD construct (25) . Despite detecting transgene expression, the Fugu HD transcript was aberrantly processed, with the inclusion of introns often giving rise to in-frame stop codons incompatible with production of full-length protein.
In this study, we have con®rmed that Fugu RNAs are spliced incorrectly in transgenic mice, consistent with the aberrant splicing of Fugu HD observed by Sathasivam et al. Our data suggest there may be a general inability of Fugu RNAs to be processed correctly in mammalian cells due to inherent differences in splicing between ®sh and mammals. Consistent with this, we show that Fugu introns are spliced correctly in transgenic zebra®sh and that the complete Fugu WT1 gene is expressed in the correct tissue-speci®c manner under its own regulatory elements. Furthermore, this expression results in correct mRNA processing and translation leading to faithful expression of the heterologous protein in transgenic zebra®sh, demonstrating for the ®rst time that Fugu genomic transgenes can be used to express Fugu proteins in transgenic zebra®sh.
MATERIALS AND METHODS

DNA constructs
WT1-containing cosmids were isolated from a gridded cosmid library of F.rubripes genomic DNA [Greg Elgar, Human Genome Mapping Project Resource Centre (HGMP-RC)], as described (10) . Unmodi®ed constructs for mouse transgenesis were isolated directly from Fugu cosmids by restriction digestion. Fugu RCN1 (Fig. 1A) was isolated as an 18 kb HindIII fragment from cosmid 151J19, and Fugu WT1 (Fig. 1C) as a 12 kb BamHI±XbaI fragment from cosmid 104M11.
The splicing construct HAFrWT1MYC was created by cloning exons 5±9 of Fugu WT1 from 151J19 (Fig. 1B) into a modi®ed pCI-neo (Promega) carrying three N-terminal haemagglutinin (HA) tags and a C-terminal myc tag (26) .
For microinjection into mouse oocytes, the transgene was liberated from vector sequences by BglII±NaeI digestion.
pXIG (a kind gift from Adam Amsterdam) consists of the green¯uorescent protein (GFP)-coding sequence under control of the Xenopus elongation factor 1a promoter. This construct directs ubiquitous GFP expression in transgenic zebra®sh (27) and was injected in its supercoiled form to obtain transient expression in zebra®sh embryos.
To create pFrWTlac for ®sh transgenesis, Fugu WT1 was ®rst cloned into pPolyIII as a 12 kb BamHI±XbaI fragment (Fig. 1C) . A b-galactosidase gene, stop and polyadenylation sequences were cloned into the SphI site in exon 9, using oligonucleotide linkers to create a fusion construct, retaining the open reading frame and allowing release of the construct by NotI digestion.
Production of transgenic animals
Constructs for transgenic mice were digested using the restriction enzymes described above, gel puri®ed to remove all vector sequences and injected into fertilised (CBA Q C57Bl/6)F 2 oocytes at~5 ng/ml. Positive founder mice were identi®ed by Southern blot, bred with (CBA Q C57Bl/6)F 1 mice and lines were maintained as heterozygotes. Transient transgenic embryos were harvested 10 days after oviduct transfer of microinjected oocytes into pseudopregnant recipients and genotyped by PCR of embryonic tail DNA with transgene-speci®c primers.
Transgenic zebra®sh were obtained by injecting single blastomeres of one-and two-cell stage zebra®sh embryos (Gol ±/± ) with pHAFrWT1MYC at~15 ng/ml. Co-injection with the ubiquitously expressing GFP vector, pXIG (27) , enabled selection of transgenic (expressing) embryos.
Analysis of transgenic animals
Total RNA was isolated from mouse tissues, whole mouse embryos and zebra®sh embryos using the RNAgents isolation system (Promega), then subjected to DNase I treatment (Roche Diagnostics) and a second phenol/choloroform extraction and precipitation. Fugu RNA was obtained from the MRC HGMP-RC and subjected to DNase I treatment (Roche Diagnostics) prior to reverse transcription. For DNA ampli®cation, Fugu RNA was subjected to PCR without reverse transcription and prior to DNase I treatment. RT±PCR was performed either by using the Access RT±PCR kit (Promega) or by reverse transcribing total RNA using an oligo(dT) primer followed by 30 cycles of intron-speci®c PCR. To control for differences in ampli®cation of particular PCR products during thermal cycling and preferential ampli®cation due to variations in template concentration, PCRs were also carried out over a range of cycle numbers (24, 26, 28 and 30 cycles) or with varying amounts of starting template. Control RT±PCRs were performed to normalise loading and verify DNase I treatment using primers for HPRT or RCN1 (mouse) and cyclin D (zebra®sh). The identity of correctly sized RT±PCR products was con®rmed by Southern blot and hybridisation with [g-32 P]ATP-labelled internal oligonucleotides (oligonucleotide sequences available on request).
For X-gal staining, zebra®sh embryos were ®xed for 45 min in 4% paraformaldehyde (PFA) at room temperature, dechorionated in phosphate-buffered saline (PBS), washed in PBS containing 0.1% Tween 20 (PBT) and stained in X-gal stain solution [Na 2 HPO 4 /NaH 2 PO 4 , NaCl, K 4 Fe 3 (CN) 6 / K 3 Fe(CN) 6 plus 0.7 mg/ml X-gal] at 37°C for between 1 and 6 h.
Zebra®sh whole-mount in situ hybridisation was performed essentially as described (28) using the full-length zebra®sh WT1 cDNA (GenBank accession no. AF144550) as a probe. Hybridisation of the digoxigenin-labelled riboprobe was detected using anti-DIG Fab-AP (1:5000) in combination with NBT/BCIP substrates (Roche). Embryos were equilibrated to 80% glycerol for photography.
RESULTS
Aberrant splicing of Fugu genes in transgenic mice
The compact nature of the Fugu genome suggests that Fugu transgenes may provide natural minigenes for transgenesis to study both gene regulation and gene function. We have previously cloned the Fugu equivalent of human chromosome 11p13, the WAGR region, and demonstrated that this locus is highly conserved between ®sh and mammals; gene order and orientation are conserved, as are numerous non-coding regions, such as known Pax6 regulatory elements (10) . This conservation implies that the Fugu WAGR region is a good model for its mammalian equivalent, and the existence of mouse strains carrying a range of deletions across this region (29, 30) makes it an attractive locus at which to perform transgenic rescue experiments in mice.
As a ®rst step towards this goal, we generated eight lines of transgenic mice via pronuclear injection of either Fugu RCN1 or Fugu WT1 into fertilised, wild-type, F 1 oocytes. Two out of the ®ve lines of Fugu RCN1 transgenic mice displayed widespread transgene expression, consistent with the expression pattern of endogenous RCN1. Transgene expression was only detectable in one line of Fugu WT1 transgenic mice, with expression restricted to the thymus (not shown). As endogenous WT1 is not expressed in the thymus, this represents a site of ectopic transgene expression, suggesting either that the Fugu WT1 transgene lacks important regulatory elements or that the species differences between puffer®sh and mammals are too great for reliable Fugu WT1 expression in transgenic mice.
We performed RT±PCR to determine whether the compact Fugu transgenes were spliced correctly and thus were capable of generating full-length protein. Consistent with previous transgenic mice expressing Fugu HD (25), aberrant splicing was observed in all three expressing lines of transgenic mice.
To investigate this aberrant splicing in detail, RT±PCR was performed on a panel of tissues from the highest expressing Fugu RCN1 line across speci®c intron±exon boundaries (Fig. 2) . Fugu RCN1 introns of <200 bp were not spliced in transgenic mice (introns 2 and 5), whilst the 1.22 kb intron 1 was fully spliced. Introns 3 and 4 (1.23 kb and 250 bp, respectively), however, were partly spliced. In contrast, RT±PCR analysis of Fugu RNA showed that the endogenous RCN1 RNA was fully spliced in vivo, with no evidence of unspliced RNA even at limiting cycle number. The doublet arising from ampli®cation of intron 4 is likely to be due to a pseudogene which has been identi®ed elsewhere in the Fugu genome. It has been suggested that Fugu introns are too small to be spliced ef®ciently by the mammalian splicing machinery (25) . The observation that Fugu RCN1 intron 1 (1.22 kb) is fully spliced whilst intron 3 (1.23 kb) is poorly spliced implies that intron size alone is not suf®cient to account for this phenomenon. Consistent with this, mammalian cells are capable of ef®ciently splicing introns of <100 bp, e.g. intron 17 of human HD is 93 bp (31) .
Ef®cient splicing of Fugu introns in transgenic zebra®sh
Given that species differences rather than intron size were the likely cause of aberrant splicing in Fugu transgenic mice, we tested whether Fugu introns could be processed correctly in a transgenic ®sh system.
To facilitate direct comparison between transgenic mice and transgenic zebra®sh, a cytomegalovirus (CMV)-driven Fugu WT1 splicing construct was utilised. This construct, pHAFrWT1MYC, consisted of a CMV promoter driving expression of a genomic fragment encompassing Fugu WT1 exons 5±9 (Fig. 1B) , with in-frame N-and C-terminal tags to facilitate speci®c detection of transgenic transcripts by RT±PCR. The Fugu WT1 introns within this construct range in size from 80 to 500 bp (Fig. 3A) .
We generated 15 transient transgenic mouse embryos with pHAFrWT1MYC. Microinjected embryos were taken at e10.5, genotyped by PCR of DNA extracted from the embryo tail and total RNA was isolated from individual whole embryos. In all transient transgenic mouse embryos, inef®cient splicing was observed across individual introns and, when splicing was analysed across two introns, almost no correctly spliced transcripts were detectable. Figure 3B shows RT±PCR analysis of splicing across exons 7±9 for two transgenic mice, M10 and M14, representative of low and high expressors, respectively. Given the inef®ciency of splicing across two introns, it is unlikely that any correctly spliced full-length mRNA would be produced in transgenic mice harbouring a complete Fugu WT1 gene. The splicing defects observed in HAFrWT1MYC transgenic embryos were not restricted to intron inclusion, with exon skipping being observed in highly expressing individuals.
The skipping of exon 8 and the correct splicing of exons 7±9 of Fugu WT1 were only detectable by conventional RT±PCR at low levels in highly expressing transgenic mice, suggesting that these are rare events and that intron inclusion is the most common splicing defect when Fugu genes are expressed in mouse cells. The inclusion of either intron 7 or intron 8 would result in four (intron 7) or three (intron 8) in-frame translational stop codons within the aberrantly spliced mRNA.
To directly compare splicing ef®ciency of this transgene between mice and ®sh, we generated transgenic zebra®sh via co-injection of pHAFrWT1MYC and pXIG. Transgenic embryos were selected for green¯uorescence at 10±12 hours post-fertilisation (h.p.f.), pooled in groups of between 15 and 30, and total RNA was isolated from separate pools for RT±PCR analysis. Two representative pools of transgenic zebra®sh embryos are shown in Figure 3B . In contrast to transgenic mouse embryos, splicing of the transgene in zebra®sh embryos was far more ef®cient. To control for saturation effects in the PCRs, ZF28 and M10 samples were subject to PCR for between 24 and 30 cycles (Fig. 3C) , showing that the aberrantly spliced RNA can be detected in transgenic mouse embryos at limiting cycle number and that no unspliced RNA is detected in transgenic zebra®sh embryos. Thus the same Fugu construct is spliced ef®ciently in zebra®sh but not in mice, suggesting that the differences affecting splicing are not speci®c to the puffer®sh but re¯ect species differences between ®sh and mammals in general.
The alternative splicing of three amino acids between zinc ®ngers 3 and 4 of WT1 is crucial for WT1 function within the genitourinary system and is conserved throughout all vertebrates (9±11). This alternative splicing event is not regulated by a tissue-speci®c factor and even occurs in transfected cells not expressing endogenous WT1 (26) . Given the ef®ciency with which the Fugu WT1 construct was spliced in transgenic zebra®sh, we used RT±PCR to determine whether the transgene was also alternatively spliced. RT±PCR analyses from exon 8 to exon 9 on pools of transgenic zebra®sh demonstrate that the Fugu WT1 construct is alternatively spliced (Fig. 3D) and that Fugu genomic transgenes have the potential to give rise to the full range of alternatively spliced WT1 transcripts in zebra®sh. We also analysed pHAFrWT1MYC transgenic mouse embryos in which low levels of correctly spliced product were observed using RT±PCR from exon 8 to exon 9 but with the addition of [ 32 P]dCTP to the reaction. By increasing sensitivity in this way, we found that the Fugu construct also exhibits alternative splicing in transgenic mice (data not shown), consistent with the ubiquitous nature of this alternative splicing event.
Protein expression from a full-length Fugu WT1 transgene in zebra®sh
The ef®ciency with which the Fugu genomic construct is spliced in ®sh suggests that full-length Fugu mRNA can be produced in transgenic zebra®sh. To test this directly and to determine whether Fugu mRNA can be translated in zebra®sh to produce full-length protein, we modi®ed the complete Fugu WT1 gene and¯anking genomic regions to include a histochemical marker (b-galactosidase) fused to the penultimate codon of WT1, such that only faithful splicing and translation of the resulting fusion mRNA would produce a fusion protein detectable by X-gal staining (Fig. 4A) .
We injected pFrWTlac into fertilised zebra®sh eggs. Approximately 10% of injected embryos displayed X-gal staining, demonstrating that the full-length genomic Fugu WT1 transgene was indeed correctly spliced and translated to produce full-length protein. Injected embryos were stained between 10 and 72 h.p.f. At 24 h.p.f., the degree of mosaicism associated with zebra®sh transgenesis resulted in expression being restriced to small`clones' of cells (data not shown). At 12 h.p.f., it was possible to identify transgenic embryos with more complete expression patternsÐtypically within the developing pronephros (Fig. 4C )Ðalthough individual embryos exhibited a great deal of mosaicism (compare Fig. 4D and E) . The expression pattern of the Fugu transgene observed at 12 h.p.f. recapitulated that of endogenous zebra®sh WT1 (Fig. 4B) . X-gal staining of zebra®sh embryos injected with pFrWTlac at later time points (48 and 72 h.p.f.) revealed no transgenic ®sh, with numerous embryos dying or developing abnormally. By performing zebra®sh injections with a modi®ed pFrWTlac (pFrWTGFP) containing GFP in place of lacZ, we con®rmed that expression of the transgene, as determined by GFP expression in un®xed zebra®sh embryos, was associated with abnormal development and lethality (not shown). This ®nding is consistent with the suggestion that overexpression of WT1 in transgenic mice causes embryonic lethality in vivo (32).
DISCUSSION
In this study, we demonstrate that Fugu transgenes are aberrantly spliced in transgenic mice and yet are correctly spliced in transgenic zebra®sh. Furthermore, we show that Fugu WT1 is expressed faithfully in the developing kidney of transgenic zebra®sh, resulting in the production of a marked Fugu WT1 protein from the transgene. These observations broaden the utility of Fugu as a model system to include Fugu introns are spliced ef®ciently in transgenic zebra®sh but not transgenic mice
The failure of Fugu transgenes to be spliced accurately in mammalian cells is consistent with a previous study of Fugu HD in which Sathasivam et al. speculate that the small size of Fugu introns stresses the ®delity of the mammalian splicing apparatus (25) . Whilst our data support this, they also suggest that the size of a particular intron is not the only factor determining whether that intron is spliced ef®ciently. Consistent with this, many mammalian introns are <250 bp (33) .
A survey of more than 100 splice site mutations found that the most common consequence of splice site mutation was exon skipping, with intron inclusion only observed in 6% of cases (34) . In contrast, intron inclusion is the most common splicing defect observed when Fugu genes are expressed in mouse cells. Therefore, it seems unlikely that speci®c sequence differences can fully explain the aberrant splicing of Fugu constructs in mouse cells, as such differences might be expected to result in exon skipping. In addition, the fact that individual Fugu introns can be partially spliced suggests that this phenomenon is related to evolutionary differences at the level of splicing ef®ciency between ®sh and mammals, in general. This implies that Fugu resembles other teleosts at the level of splicing despite its compact genome. It may be that these evolutionary differences between splicing in ®sh and mammals could be exploited to further understand the fundamental mechanisms underlying splicing in vertebrates.
Typically, vertebrate genes possess large introns and small exons, whilst the genes of lower eukaryotes possess small introns and relatively large exons (35) . These differences form the basis of the intron versus exon de®nition models of splicing (36) . Fugu, however, is an exception in that its genes display vertebrate exon organisation with generally small introns (17) . This reduction in intron size whilst retaining exon size compared with other vertebrates may, as these models predict, stress the ®delity of the splicing machinery of mouse cells. Intriguingly, the observation that Fugu introns are spliced ef®ciently in zebra®sh would suggest general species differences in intron versus exon de®nition between ®sh and mammals, rather than a phenomenon unique to Fugu. Crossspecies transgenesis may provide an interesting way in which to study these fundamental splicing decisions which, to date, have been addressed by making changes to a splicing construct within a constant cell system. By keeping the splicing construct constant and changing the cell (species) type, parameters such as ionic strength, factor concentration and temperature may be affecting the activity of splicing factors or the con®guration of pre-mRNA (37±39). In light of this, it is interesting to note the recent characterisation of an alternative splicing event within the human neuro®bromatosis type 1 mRNA which is induced by cold stress of 25°C (40) .
The genomes of both the puffer®sh (http://fugu. hgmp.mrc.ac.uk) and the zebra®sh (http://www.sanger.ac.uk/ Projects/D_rerio) are in the process of being fully sequenced. The complete genome sequence of these two teleost ®sh will enable detailed genomic comparisons to be made between ®sh and mammals, and will complement cross-species transgenic experiments of the kind described herein. In particular, the comparison of transgenic mice harbouring zebra®sh genomic clones with mice harbouring puffer®sh genomic constructs would address the issue of whether these splicing differences truly are teleost speci®c and also serve as a valuable experimental resource for investigating the mechanism of such differences.
Faithful expression of a marked Fugu WT1 protein in transgenic zebra®sh
The sequences regulating the expression of WT1 in vivo have yet to be identi®ed. The proximal promoter of the human gene directs variable expression of a reporter gene in transgenic mice and not in the major site of WT1 expression, the developing genitourinary system (41) . A 280 kb human WT1 yeast arti®cial chromosome (YAC) is required to achieve correct genitourinary expression of a reporter gene in transgenic mice (41, 42) although expression of this construct is in¯uenced by its site of integration. Despite the bene®ts of recombination in yeast to modify constructs, YAC transgenesis as a means of dissecting gene regulation is costly and time consuming. The conservation of genitourinary WT1 expression throughout vertebrates suggests that gene regulation studies in lower vertebrates and comparative evolutionary approaches may be appropriate for WT1. The puffer®sh genome is approximately 7.5 times smaller than that of human (17) , whilst the Fugu WT1 gene is approximately 15 times smaller than its human counterpart (10) . We demonstrate that, despite this compaction, the Fugu WT1 gene can faithfully recapitulate the expression pattern of the endogenous zebra®sh WT1 gene when introduced as a transgene.
The inability to detect expression of Fugu WT1 in the kidneys of transgenic mice may be due to the mammalian transcription machinery not recognising Fugu WT1 elements ef®ciently or, as with the analogous human construct, may re¯ect a great sensitivity to site of integration effects. That a similar Fugu construct directs reproducible kidney-speci®c expression in transgenic zebra®sh further strengthens the case for the Fugu:zebra®sh system as a means of dissecting gene regulation in vivo, and provides a genetic tool for studying pronephric development in zebra®sh via transgenesis.
Whilst this study con®rms that Fugu genes do not function as natural minigenes in transgenic mice, full-length Fugu WT1 with a C-terminal b-galactosidase fusion is correctly spliced and translated to produce the fusion protein in transgenic zebra®sh. These studies suggest that Fugu genes will be useful for functional transgenic experiments in zebra®sh. For example, Fugu cosmids introduced into zebra®sh mutants could be employed in transgenic rescue experimentsÐFugu genes can express faithfully in zebra®sh, Fugu mRNAs can be processed to give protein and Fugu clones are available`off the shelf' from the UK HGMP-RC (http://fugu.hgmp.mrc. ac.uk). Given the increasing number of zebra®sh mutants available, this approach could have broad implications. The zebra®sh:Fugu system now represents a powerful and convenient tool for dissecting both vertebrate gene regulation and gene function in vivo and may help in the study of the fundamental mechanisms underlying vertebrate splicing.
